3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
5
Neoplasms by Histologic Type
4
Neoplasms
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Chronic-Phase
3
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Blast Crisis
1
Interventions
Bevacizumab
9
Oxaliplatin
7
Irinotecan
6
Fluorouracil
6
Nivolumab
5
Leucovorin
5
Cetuximab
5
Capecitabine
5
pembrolizumab
4
Sunitinib
4
IFL protocol
4
Drug Therapy
4
Cisplatin
4
encorafenib
3
Pemetrexed
3
Gemcitabine
3
Folfox protocol
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
trastuzumab deruxtecan
2
amminedichloro(2-methylpyridine)platinum(II)
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Levoleucovorin
2
IDRX-42
2
CGX1321
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
ulixertinib
1
tivozanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts